A prospective, interventional, case control study to observe and assess the safety and efficacy of Unani regimen in preventing the progression of severity of the disease in hospitalized SARS-CoV2 tested positive asymptomatic /mild to moderate symptomatic COVID-19 cases, managed as per Govt of India COVID-19 management guidelines, at a COVID-19 management facility

Central Council for Research in Unani Medicine CCRUM New Delhi0 个研究点目标入组 62 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients of either sex aged between 18-65 years
•2. Patients who have been tested positive with SARS-CoV2 virus
•Asymptomatic Patients
•Patients with mild symptoms
•Patients with moderate symptoms with respiratory rate < 30 per minute and oxygen
•saturation > 90%
•3. Voluntariness to participate in the trial
•USCDC classification mild to moderate, severe and critical stages of COVID-19
•Stage Features
•Asymptomatic No specific clinical symptoms of COVID-19 disease
•Mild to Moderate Mild clinical symptoms up to mild pneumonia
•Severe Dyspnea, hypoxia, or >50% lung involvement on imaging
•Critical Respiratory failure, shock, or multiorgan system dysfunction

•The subject must be excluded from participating in the trial if they fulfill anyone of the criteria as
•mentioned below:
•1. COVID-19 patients with symptoms classified as severe or critical.
•2. Suspected COVID-19, not tested positive for COVID-19 by RT-PCR
•3. Persons with severe primary respiratory disease or pneumonia
•4. Pregnant and lactating women
•5. Persons with serious diseases such as Cancer, Heart Disease, Stroke, Disabilities, Mental
•illnesses, etc., and who are considered to be excluded from the study as evaluated by the
•investigators
•6. COVID-19 positive cases participating as subjects in the interventional arm of other
•COVID-19 clinical trials

发起方

Central Council for Research in Unani Medicine CCRUM New Delhi